|Day Low/High||27.19 / 28.74|
|52 Wk Low/High||22.76 / 59.25|
Constellation Brands is the kind of company that typically does well in a weak market environment.
Canopy Growth has corrected to the downside in recent days.
Canopy Growth already has a $4 billion war chest thanks to Constellation Brands.
The company's intention to list on the NYSE is just one positive it has going for it.
MSFT is never going to be a big time growth stock again.
Here's a bit of breaking news: More fuel for marijuana stocks as a few minutes ago on CNBC Canopy Growth Corp. CEO Bruce Linton said the government will soon approve new products so the company can be more competitive.
As I mentioned earlier, we're off to a brisk pace this morning, and here are some of the headlines that have caught my eye as I drink that second cup of coffee: * US Bancorp reports September quarter earnings per share that were $0.02 ahead of expec...
Wednesday is the first day for legalized cannabis sales in Canada.
On Wednesday, Canada becomes the first major economy to legalize the recreational use of cannabis.
But don't buy into this overheated market right as Canada legalizes, wait until prices come down -- which they will.
There just isn't any worry right now that this market is going to start moving back up with conviction.
Will it be too painful to stick around while you wait for the Fed to change course?
This is a stock with a terrible chart and questionable financials.
The time to scoop up Altria is now, not when some type of official announcement is made.
These stocks offer some diversification or unique features in the legal-weed space.
Canopy Growth could be Constellation's next big growth engine.
Shareholders enjoyed a crisp day of gains after Constellation cracked open a great earnings report pre-market.
Investors and experts need more time before they go all in on cannabis.
Market experts are abuzz over Constellation's potential new inroads into the cannabis market.
It's too easy to lump all cannabis-related stocks into the moniker "marijuana." Like many other sectors, there are differentiators underneath the same way we see in semiconductors or retail or even energy. As you go down the marijuana rabbit hole, ...
With STZ's earnings beat and the potential of the CGC investment, investors are willing to pay a premium.
I have no problem blessing an investment in this name with the appropriate steps taken toward risk management.
Constellation looks to wine, beer, and cannabis to take it higher.
There are several avenues to invest in the potential cannabis boom -- recreational plays; medical plays; and companies that have a lot to gain from the industry but aren't reliant upon it for success.
I have the honor and pleasure of book-ending your week away from Doug. On Friday, we'll get non-farm payroll and the unemployment, so I don't put much stock in the data coming this Thursday morning. Instead, I want to start off the day talking abou...
Constellation looks like a star today after beating expectations.
The market is in no mood to give the benefit of the doubt to a stock acting as poorly as Facebook.
Painkiller manufacturers might see their profits hurt by medical cannabis in the near future.